US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
US5849905A
(en)
*
|
1994-11-23 |
1998-12-15 |
Centre National De La Recherche Scientifique |
Biologically active phosphotriester-type nucleosides and methods for preparing same
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US5985558A
(en)
|
1997-04-14 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
|
JPH09504785A
(ja)
|
1993-09-10 |
1997-05-13 |
エモリー、ユニバーシティー |
抗b型肝炎ウイルス活性を有するヌクレオシド
|
US20020120130A1
(en)
|
1993-09-10 |
2002-08-29 |
Gilles Gosselin |
2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
|
FR2733234B1
(fr)
*
|
1995-04-21 |
1997-07-04 |
Centre Nat Rech Scient |
Derives de l'acyclovir comme agents antiviraux
|
AU5511196A
(en)
*
|
1995-04-21 |
1996-11-07 |
Centre National De La Recherche Scientifique (Cnrs) |
Acyclovir derivatives as antiviral agents
|
CA2219132C
(en)
|
1995-06-07 |
2007-03-06 |
Emory University |
Nucleosides with anti-hepatitis b virus activity
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US6716625B1
(en)
|
1997-04-16 |
2004-04-06 |
Claude Selitrennikoff |
Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
|
US6528271B1
(en)
|
1997-06-05 |
2003-03-04 |
Duke University |
Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
|
JP2002510319A
(ja)
|
1997-07-01 |
2002-04-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US5877309A
(en)
*
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
US5968748A
(en)
*
|
1998-03-26 |
1999-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human HER-2 expression
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6684250B2
(en)
|
2000-04-03 |
2004-01-27 |
Quova, Inc. |
Method and apparatus for estimating a geographic location of a networked entity
|
US7279324B2
(en)
|
2001-01-23 |
2007-10-09 |
Duke University |
Nucleic acid encoding G-protein coupled receptor with modified DRY motif
|
EP1404698A4
(de)
|
2001-06-21 |
2004-12-22 |
Isis Pharmaceuticals Inc |
Antisense-modulation von superoxiddismutase 1, expression in lösung
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ577565A
(en)
|
2001-10-09 |
2010-10-29 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
JP2005523922A
(ja)
|
2002-04-26 |
2005-08-11 |
ギリアード サイエンシーズ, インコーポレイテッド |
非ヌクレオシド逆転写酵素阻害剤
|
CA2498777C
(en)
|
2002-09-13 |
2015-01-13 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
AU2003278957A1
(en)
|
2002-09-26 |
2004-04-23 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
AU2003291755A1
(en)
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
JP4986109B2
(ja)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
アポリポタンパク質b発現のアンチセンス調節
|
EP2336319A1
(de)
|
2002-11-13 |
2011-06-22 |
Genzyme Corporation |
Antisense-Modulation von Apolipoprotein-B-Expression
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
CA2515484C
(en)
|
2003-02-11 |
2011-09-20 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
US8084432B2
(en)
|
2003-02-13 |
2011-12-27 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of pouchitis
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
EA200501676A1
(ru)
|
2003-04-25 |
2006-04-28 |
Джилид Сайэнс, Инк. |
Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
|
WO2004096285A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-infective phosphonate conjugates
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
US7427636B2
(en)
|
2003-04-25 |
2008-09-23 |
Gilead Sciences, Inc. |
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
|
WO2004096233A2
(en)
*
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
ATE490788T1
(de)
|
2003-04-25 |
2010-12-15 |
Gilead Sciences Inc |
Antivirale phosphonate analoge
|
BRPI0410886A
(pt)
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
EP2256201A3
(de)
|
2003-09-18 |
2012-07-04 |
Isis Pharmaceuticals, Inc. |
Modulation der eIF4E expression
|
EP1677822B1
(de)
|
2003-09-18 |
2014-04-23 |
Isis Pharmaceuticals, Inc. |
4'-thionucleoside und oligomere verbindungen
|
ES2437491T3
(es)
|
2003-10-10 |
2014-01-10 |
Alchemia Oncology Pty Limited |
Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad
|
JP2007508844A
(ja)
|
2003-10-24 |
2007-04-12 |
ギリアード サイエンシーズ, インコーポレイテッド |
治療用化合物の同定のための方法および組成物
|
WO2005044279A1
(en)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Purine nucleoside phosphonate conjugates
|
US7432273B2
(en)
|
2003-10-24 |
2008-10-07 |
Gilead Sciences, Inc. |
Phosphonate analogs of antimetabolites
|
EA015670B9
(ru)
|
2003-12-03 |
2012-01-30 |
Коуда Терапьютикс (Нз) Лтд. |
Антисмысловые соединения, нацеленные на коннексины, и способы их применения
|
DE602004019815D1
(de)
|
2003-12-22 |
2009-04-16 |
Gilead Sciences Inc |
4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung
|
WO2005089268A2
(en)
|
2004-03-15 |
2005-09-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of rna by rnase h
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
AU2011218664B2
(en)
*
|
2004-07-27 |
2014-08-21 |
Gilead Sciences, Inc. |
Antiviral compounds
|
PT2258376T
(pt)
*
|
2004-07-27 |
2019-05-31 |
Gilead Sciences Inc |
Análogos fosfonatados de compostos inibidores do vih
|
DK2997980T3
(en)
|
2004-08-10 |
2018-03-26 |
Kastle Therapeutics Llc |
PROCEDURES FOR MODULATING LIPROPROTEIN AND CHOLESTEROL LEVELS
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
PT1809303T
(pt)
|
2004-09-23 |
2019-06-17 |
Arc Medical Devices Inc |
Composições farmacêuticas e métodos relacionados para inibir aderências fibrosas ou doença inflamatória com a utilização de fucanos com baixo teor de sulfato
|
US8765700B2
(en)
|
2004-10-20 |
2014-07-01 |
Antisense Therapeutics Ltd. |
Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions
|
EP1959981B1
(de)
|
2005-02-03 |
2019-10-16 |
Coda Therapeutics Limited |
Anti-connexin 43-verbindungen zur behandlung von chronischen wunden
|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
AU2006216514C1
(en)
|
2005-02-25 |
2012-09-27 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to IL-4R alpha
|
AU2006235451A1
(en)
|
2005-04-08 |
2006-10-19 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to acetyl-CoA carboxylases
|
US20060258610A1
(en)
|
2005-05-12 |
2006-11-16 |
Isis Pharmaceuticals, Inc. |
Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
|
EP2462937A1
(de)
|
2005-05-24 |
2012-06-13 |
Isis Pharmaceuticals, Inc. |
Modulation von LMW-PTPasen-Expression
|
WO2006127976A2
(en)
|
2005-05-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to ptpru
|
EP2548560B1
(de)
|
2005-06-23 |
2015-06-03 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Modulation der SMN2-Aufspaltung
|
WO2007014352A2
(en)
*
|
2005-07-27 |
2007-02-01 |
Gilead Sciences, Inc. |
Antiviral phosphonate conjugates for inhibition of hiv
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
EP1991677A2
(de)
|
2006-01-26 |
2008-11-19 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und deren auf huntingtin gerichtete verwendungen
|
US8076306B2
(en)
|
2006-04-12 |
2011-12-13 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hepcidin
|
AU2007245599B2
(en)
|
2006-05-03 |
2012-05-10 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
EP2023940B1
(de)
|
2006-05-05 |
2011-06-22 |
Isis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation der expression von sglt2
|
EP2527442A3
(de)
|
2006-05-05 |
2013-03-06 |
Isis Pharmaceuticals, Inc. |
Verbindungen und Verfahren zur Modulation von Genexpression
|
WO2007131232A2
(en)
|
2006-05-05 |
2007-11-15 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to ptpr alpha
|
WO2008017081A1
(en)
|
2006-08-04 |
2008-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of jnk proteins
|
DK2410054T4
(da)
|
2006-10-18 |
2020-02-10 |
Ionis Pharmaceuticals Inc |
Antisenseforbindelser
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US8048998B2
(en)
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
EP2291200A4
(de)
|
2008-05-22 |
2012-05-30 |
Isis Pharmaceuticals Inc |
Verfahren zur modulierung der expression von rbp4
|
KR20110065440A
(ko)
*
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
US20100093667A1
(en)
|
2008-07-08 |
2010-04-15 |
Gilead Sciences, Inc. |
Salts of hiv inhibitor compounds
|
US20110172293A1
(en)
|
2008-07-08 |
2011-07-14 |
Fish Jason E |
Methods and Compositions for Modulating Angiogenesis
|
EP3081648A1
(de)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
|
EP2342616A2
(de)
|
2008-09-23 |
2011-07-13 |
Alnylam Pharmaceuticals Inc. |
Chemische modifikationen von monomeren und oligonukleotiden mit cycloaddition
|
WO2010120524A2
(en)
|
2009-03-31 |
2010-10-21 |
Altair Therapeutics, Inc. |
Methods of modulating an immune response to a viral infection
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
TWI515000B
(zh)
|
2010-04-01 |
2016-01-01 |
伊迪尼克製藥公司 |
用於治療病毒感染之化合物及醫藥組合物
|
JP6177692B2
(ja)
|
2011-02-02 |
2017-08-09 |
エクスカリアード・ファーマシューティカルズ,インク |
結合組織増殖因子(ctgf)をターゲティングするアンチセンス化合物を用いた、ケロイドまたは肥厚性瘢痕の治療法
|
WO2012109395A1
(en)
|
2011-02-08 |
2012-08-16 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
CA2843324A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
DK2742136T3
(da)
|
2011-08-11 |
2017-11-20 |
Ionis Pharmaceuticals Inc |
Gapmerforbindelser omfattende 5'-modificerede deoxyribonukleosider i gap og anvendelser deraf
|
EP2755983B1
(de)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituierte carbonyloxymethylphosphoramidatverbindungen und pharmazeutische zusammensetzungen zur behandlung von virusinfektionen
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
ES2734495T3
(es)
|
2011-12-22 |
2019-12-10 |
Geron Corp |
Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
|
CN102613190A
(zh)
*
|
2012-03-07 |
2012-08-01 |
海南正业中农高科股份有限公司 |
壳寡糖用于提高坐果率的用途
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
AU2013306006B2
(en)
|
2012-08-20 |
2017-07-06 |
The Regents Of The University Of California |
Polynucleotides having bioreversible groups
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
WO2014092572A1
(en)
|
2012-12-12 |
2014-06-19 |
Universiteit Leiden |
Improved methods for cancer treatment with a genotoxic agent
|
DK3007704T3
(da)
|
2013-06-13 |
2021-03-29 |
Antisense Therapeutics Ltd |
Kombinationsterapi til akromegali
|
EP3041935A1
(de)
|
2013-09-05 |
2016-07-13 |
Sage Therapeutics, Inc. |
Antisense-induzierter exon2-einschluss in saurer alpha-glucosidase
|
CN106661580B
(zh)
|
2014-06-10 |
2022-02-15 |
鹿特丹伊拉斯谟大学医疗中心 |
用于治疗庞帕病的反义寡核苷酸
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
MA50829A
(fr)
|
2015-06-01 |
2018-04-11 |
Sarepta Therapeutics Inc |
Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
|
AU2016287585B2
(en)
|
2015-07-02 |
2020-12-17 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
EP3359668A4
(de)
|
2015-10-09 |
2019-06-05 |
Sarepta Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen
|
AU2016349954B2
(en)
|
2015-11-05 |
2022-08-25 |
Antisense Therapeutics Ltd |
Mobilizing leukemia cells
|
EP3387127A1
(de)
|
2015-12-07 |
2018-10-17 |
Erasmus University Medical Center Rotterdam |
Enzymatische ersatztherapie und antisense-therapie für pompe-krankheit
|
AU2017254106B2
(en)
|
2016-04-18 |
2024-07-11 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
US11981703B2
(en)
|
2016-08-17 |
2024-05-14 |
Sirius Therapeutics, Inc. |
Polynucleotide constructs
|
WO2019006455A1
(en)
|
2017-06-30 |
2019-01-03 |
Solstice Biologics, Ltd. |
AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
|
US10688112B2
(en)
|
2017-07-13 |
2020-06-23 |
Emory University |
Lipid disulfide prodrugs and uses related thereto
|
EP3661937B1
(de)
|
2017-08-01 |
2021-07-28 |
Gilead Sciences, Inc. |
Kristalline formen von ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninat (gs-9131) zur behandlung von viralen infektionen
|
KR20200035438A
(ko)
|
2017-08-03 |
2020-04-03 |
오쓰까 세이야꾸 가부시키가이샤 |
약물 화합물 및 이의 정제 방법
|
JP7282379B2
(ja)
*
|
2017-08-22 |
2023-05-29 |
国立大学法人東海国立大学機構 |
修飾ポリヌクレオチド
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
EP4005602A4
(de)
|
2019-07-30 |
2024-06-12 |
Shionogi & Co., Ltd |
Gegen murf1 gerichteter nukleinsäurewirkstoff
|
JP2022546310A
(ja)
|
2019-08-22 |
2022-11-04 |
エモリー ユニバーシティー |
ヌクレオシドプロドラッグ及びそれに関する使用
|